New clinical trials are ongoing to study new anti-obesity drugs, such as sodium-glucose cotransporter two inhibitors, other GLP-1 receptor agonists, dopamine reuptake inhibitors or mineralocorticoid receptor agonists (114). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.